Augmentation of immune checkpoint cancer immunotherapy with IL18

Clinical Cancer Research

Volumn 22, Issue 12, 2016, Pages 2969-2980

  Ma, Zhifeng ^a   Li, Wen ^a   Yoshiya, Shinichi ^a   Xu, Yunfeng ^a   Hata, Masaki ^a   El Darawish, Yosif ^a   Markova, Tzvetanka ^a   Yamanishi, Kyosuke ^b   Yamanishi, Hiromichi ^b   Tahara, Hideaki ^c   Tanaka, Yoshimasa ^d   Okamura, Haruki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Hirakata Ryoikuen ^*  (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIPROGRAMMED DEATH 1 LIGAND 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GANGLIOSIDE GM1 ANTIBODY; INTERLEUKIN 18; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CD274 PROTEIN, MOUSE; CTLA4 PROTEIN, MOUSE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CARCINOMA; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CT 26 CELL LINE; DRUG EFFECT; IMMUNOMODULATION; MALE; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; TUMOR REJECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; EXPERIMENTAL MELANOMA; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; REGULATORY T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CTLA-4 ANTIGEN; IMMUNOTHERAPY; INTERLEUKIN-18; KILLER CELLS, NATURAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, ANIMAL; T-LYMPHOCYTES, REGULATORY;

EID: 84975123267     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1655     Document Type: Article

References (42)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
2. Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 2015;75:5-10.
3. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol 2015;6:418.
4. Zhou E, Huang Q, Wang J, Fang C, Yang L, Zhu M, et al. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol 2015;8:8018-27.
5. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
6. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001;194:481-9.
7. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
8. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77.
9. Korman A, Yellin M, Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 2005;6:582-91.
10. Agarwala SS, Ribas A. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 2010;33:557-69.
11. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015;21:24-33.
12. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
13. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044-51.
14. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947-53.
15. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128:887-96.
16. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73:3591-603.
17. Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013;94:25-39.
18. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-65.
19. Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, Beer HD. Caspase-1: the inflammasome and beyond. Innate Immun 2014;20:115-25.
20. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012;13:343-51.
21. Kolb R, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell 2014;5:12-20.
22. Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M, et al. Interleukin 18: friend or foe in cancer. Biochim Biophys Acta 2013;1836:296-303.
23. Ortaldo JR, Young HA. IL18 as critical co-stimulatory molecules in modulating the immune response of ITAM bearing lymphocytes. Semin Immunol 2006;18:193-6.
24. Hodge DL, Subleski JJ, Reynolds DA, Buschman MD, Schill WB, Burkett MW, et al. The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death. J Interferon Cytokine Res 2006;26:706-18.
25. Li W, Kashiwamura S, Ueda H, Sekiyama A, Okamura H. Protection of CD8+ T cells from activation-induced cell death by IL18. J Leukoc Biol 2007;82:142-51.
26. Li W, Kubo S, Okuda A, Yamamoto H, Ueda H, Tanaka T, et al. Effect of IL18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother 2010;33:287-96.
27. Tsuda J, Li W, Yamanishi H, Yamamoto H, Okuda A, Kubo S, et al. Involvement of CD56brightCD11c+ cells in IL18-mediated expansion of human γα T cells. J Immunol 2011;186:2003-12.
28. Guimont-Desrochers F, Lesage S. Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells. Front Immunol 2013;4:446.
29. Zitvogel L, Housseau F. IKDCs or B220+ NK cells are pre-mNK cells. Blood 2012;119:4345-6.
30. Glockzin G, Piso P. Current status and future directions in gastric cancer with peritoneal dissemination. Surg Oncol Clin N Am 2012;21:625-33.
31. Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colom, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie 2011;34:101-8.
32. Takiguchi S, Nishino Y, Inoue K, Ikeda M, Kataoka Y, Matsusue K, et al. The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model. Oncol Rep 2012;28:111-6.
33. Kuramoto Y, Kawakami S, Zhou S, Fukuda K, Yamashita F, Hashida M. Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. J Control Release 2008;126:274-80.
34. Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2015Oct 29 [Epub ahead of print].
35. Kroeger KM, Sullivan BM, Locksley RM. IL18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. J Leukoc Biol 2009;86:769-78.
36. Chandrasekar B, Mummidi S, Valente AJ, Patel DN, Bailey SR, Freeman GL, et al. The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 2005;280:26263-77.
37. Reddy VS, Harskamp RE, van Ginkel MW, Calhoon J, Baisden CE, Kim IS, et al. Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. J Cell Physiol 2008;215:697-707.
38. Li W, Yamamoto H, Kubo S, Okamura H. Modulation of innate immunity by IL18. J Reprod Immunol 2009;83:101-5.
39. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001;19:423-74.
40. Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, et al. Cancer-induced immunosuppression: IL18-elicited immunoablative NK cells. Cancer Res 2012;72:2757-67.
41. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, et al. IL18 Induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011;71:5393-9.
42. Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL18 in cancer biology and counter-regulation by IL18BP. J Leukoc Biol 2015;97:665-75.